The main driving force behind the global continuous bioprocessing market is the fundamental goal to enhance biopharmaceutical production. This enhancement aims at boosting yield, flexibility, productivity, and product consistency, while simultaneously cutting down on the overall costs of manufacturing.
As per the report published by BIS Research, the global continuous bioprocessing market was valued at $250.1 million in 2023 and is expected to reach $1,639.1 million by 2033, growing at a CAGR of 20.68% between 2023 and 2033.
In recent years, the continuous bioprocessing method for producing uniform products has gained considerable popularity. While the adaptation of continuous upstream bioprocessing has been established, there is currently a significant push towards incorporating downstream bioprocessing into continuous operations as well.
Based on BioPlan's 18th Annual Report survey, over 40% of participants identified continuous upstream processing as the second most evaluated system for potential implementation in the bioprocessing industry by 2024.
Despite the limited application of continuous bioprocessing in approved commercial productions to date, there's a growing interest among leading companies to overcome the hurdles associated with adopting continuous bioprocessing techniques in manufacturing, which has propelled market growth.
Early adopters pioneering this approach include notable firms such as Alvotech, Amgen, BiosanaPharma, Boehringer Ingelheim, Enzene, Genzyme, Transcenta Holdings, Just Biotherapeutics, Novartis, Pfizer, among others.
Segmentation 1: by Product
• Chromatography Systems and Consumables
• Filtration Systems and Devices
• Bioreactors
• Cell Culture Media, Cell Lines, Buffers, and Reagents
• Other Products
Segmentation 2: by Process
• Downstream Bioprocess
• Upstream Bioprocess
Segmentation 3: by Application
• Monoclonal Antibodies
• Vaccines
• Cell and Gene Therapy
• Other Applications
Segmentation 4: by End User
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations
Segmentation 5: by Region
• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Netherlands
o Rest-of-Europe
• Asia-Pacific
o Japan
o India
o China
o South Korea
o Australia
o Rest-of-Asia-Pacific
• Latin America
o Brazil
o Mexico
o Rest-of-Latin America
• Rest-of-the-World
In June 2023, Waters and Sartorius extended their collaboration to create integrated analytical tools for downstream biomanufacturing, building on their previous success in upstream process enhancements.
In September 2023, Sartorius and Repligen Corporation unveiled a new integrated system combining Biostat STR with XCell ATF, aimed at intensifying upstream processes.
In February 2021, 3M Health Care launched the 3M Polisher ST, an innovative, single-use AEX solution designed to replace the conventional reusable AEX polishing columns in biologic drug production. The Polisher ST aims to streamline the biopharmaceutical manufacturing workflow by reducing the number of processing steps, thereby improving process efficiency and offering economic advantages.
As of 2022, companies in the chromatography systems and consumables sector dominated the market, securing roughly 32.99% of market share. Meanwhile, the filtration systems and devices segment represented about 28.42% of the market's share in the same year. The remaining product categories collectively accounted for 38.59% of the market presence.
Some prominent names established in this market are:
• 3M
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Sartorius AG
• Danaher Corporation
• Corning Incorporated
• Repligen Corporation
• Eppendorf AG
• Entegris, Inc.
• Meissner Filtration Products Inc.
• Kuhner AG
• OmniBRx Biotechnologies Pvt Ltd.
• Bionet
• Solesis Medical
According to Swati Sood, Principal Analyst – BIS Research, “The continuous bioprocessing market is witnessing transformative growth, driven by the biopharmaceutical industry's push for more efficient, cost-effective, and flexible manufacturing solutions. Continuous bioprocessing, owing to its potential to streamline operations and enhance product quality, is rapidly moving from an innovative concept to an essential strategy for companies aiming to stay competitive in a fast-evolving landscape.
The adoption of continuous bioprocesses is not just a technological upgrade but a strategic pivot toward sustainability, agility, and regulatory compliance. Key trends within the market include the integration of advanced analytics, the rise of single-use technologies, and the emphasis on partnerships to accelerate technological advancements and adoption."
